Arcoma

Arcoma Net Debt/Equity

The Net Debt to Equity Ratio of Arcoma (ARCOMA.ST) as of Oct 23, 2026 is -0.47. In the previous year, Net Debt to Equity Ratio was -0.22 — a change of 110.04% (lower).

Net Debt/Equity

-0.47

YoY

110.04%

Last updated:

Net Debt to Equity Ratio of Arcoma is 2025 -0.47 . Net Debt to Equity Ratio of Arcoma was 2024 -0.22 . It decreases by 110.04% lower compared to the previous year.

The Arcoma Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
0.14 SEK
Jan 1, 2019
0.11 SEK
Jan 1, 2020
0.17 SEK
Jan 1, 2021
0.27 SEK
Jan 1, 2022
0.34 SEK
Jan 1, 2023
-0.02 SEK
Jan 1, 2024
-0.22 SEK
Jan 1, 2025
-0.47 SEK
The Arcoma Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.47+110.04%
-0.22+868.14%
-0.02-106.89%
0.34+25.78%
0.27+57.25%
0.17+51.58%
0.11-20.93%
0.14-318.00%
-0.07-121.82%
0.30+151.44%
0.12-59.34%
0.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

Net Debt to Equity Ratio of Arcoma is -0.47 in 2025.

Net Debt to Equity Ratio of Arcoma changed from -0.22 to -0.47, representing a 110.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Arcoma since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Arcoma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Arcoma

All Key Metrics — Arcoma